Immunosenescence: Can Aging Immune Responses Impact Transplant Outcomes? iconImmunosenescence: Can Aging Immune Responses Impact Transplant Outcomes?

Immunosenescence: Can Aging Immune Responses Impact Transplant Outcomes?

Feb 15, 2014 11:00am ‐ Feb 15, 2014 11:30am

Identification: SA02b

Dr. Kirk provides an overview of the efficiency of the immune system with age and the impact of T cell exhaustion on rejection. Does immune-senescence exist in patients or is this an animal model phenomenon? Should this alter how we follow T cell markers in patients or treat patients?
Fibrosis and EMT: Is It a Marker, Is It a Target, or Is It Just "Noise"? iconFibrosis and EMT: Is It a Marker, Is It a Target, or Is It Just "Noise"?

Fibrosis and EMT: Is It a Marker, Is It a Target, or Is It Just "Noise"?

Feb 15, 2014 11:30am ‐ Feb 15, 2014 12:00pm

Identification: SA02c

EMT contribution to fibrosis in the kidney has been controversial. Is transplant the right model for EMT or not? What is the latest view on this, and how can we alter fibrosis? Is inflammation always required for graft loss or is fibrosis a terminal event?
Targeting Fibrosis Clinically: Can We Extend Results in Liver to Solid Organ Transplantation? iconTargeting Fibrosis Clinically: Can We Extend Results in Liver to Solid Organ Transplantation?

Targeting Fibrosis Clinically: Can We Extend Results in Liver to Solid Organ Transplantation?

Feb 15, 2014 12:00pm ‐ Feb 15, 2014 12:30pm

Identification: SA02d

Fibrosis in the liver may be under the control of mechanisms not seen in the kidney. What is the evidence that targeting fibrosis has a role in liver injury and function?
Are HLA Antibodies Important in Late Allograft Loss? iconAre HLA Antibodies Important in Late Allograft Loss?

Are HLA Antibodies Important in Late Allograft Loss?

Feb 15, 2014 3:00pm ‐ Feb 15, 2014 3:30pm

Identification: SA03a

Anti HLA antibodies have been shown to be associated with acute and chronic allograft dysfunction in multiple studies. However, the degree to which they account for late allograft loss has been debated. Are anti HLA antibodies the sole cause of late allograft loss and if so, how much can this response be modified?
How Many Ways Can You Activate or Injure Endothelium? Can You Turn It Off? iconHow Many Ways Can You Activate or Injure Endothelium? Can You Turn It Off?

How Many Ways Can You Activate or Injure Endothelium? Can You Turn It Off?

Feb 15, 2014 3:30pm ‐ Feb 15, 2014 4:00pm

Identification: SA03b

While recent developments in transplantation have focused on the role of antibodies and complement activation in allograft dysfunction, it can be argued that the transplant community needs to step and look at the bigger picture of endothelial cell activation that can occur through multiple potential mechanisms, of which antibody mediated activation is one.
Chronic Control of Complement in Antibody-mediated Rejection: Does this "Extinguish" Inflammation? iconChronic Control of Complement in Antibody-mediated Rejection: Does this "Extinguish" Inflammation?

Chronic Control of Complement in Antibody-mediated Rejection: Does this "Extinguish" Inflammation?

Feb 15, 2014 4:00pm ‐ Feb 15, 2014 4:30pm

Identification: SA03c

Inflammation by itself increases antibody levels, which contributes to chronic injury. Can the control of complement by itself extinguish inflammation and is this the best strategy to deal with chronic antibody rejection? Are there alternative approaches other than anti C5 antibody?
Chronic Antibody-mediated Rejection: "Too little or "Too much" Immunosuppression? iconChronic Antibody-mediated Rejection: "Too little or "Too much" Immunosuppression?

Chronic Antibody-mediated Rejection: "Too little or "Too much" Immunosuppression?

Feb 15, 2014 4:30pm ‐ Feb 15, 2014 5:00pm

Identification: SA03d

Intuitively the presence of antibody should reflect insufficient immunosuppression. Alternatively injury of tissue with excessive immunosuppression that leads to the loss of regulatory cell function may contribute to chronic antibody and immune responses. What is the effect of drug therapies on antibody generation and are they inadequate or excessive?
Did Our Drugs 'Fail Our Patients' or Did Our Trials 'Fail Our Drugs'? iconDid Our Drugs 'Fail Our Patients' or Did Our Trials 'Fail Our Drugs'?

Did Our Drugs 'Fail Our Patients' or Did Our Trials 'Fail Our Drugs'?

Feb 15, 2014 5:30pm ‐ Feb 15, 2014 6:00pm

Identification: SA04a

This talk will set the discussion and outline current testing of drugs and how our approaches may have been limiting and inadequate. Did traditional trial endpoints terminate drugs that should have succeeded? Could genomics or alternative endpoints have impacted clinical trial design?
Why Aren't We Using All the Molecular Diagnostic Tools We Keep Hearing About? iconWhy Aren't We Using All the Molecular Diagnostic Tools We Keep Hearing About?

Why Aren't We Using All the Molecular Diagnostic Tools We Keep Hearing About?

Feb 15, 2014 6:30pm ‐ Feb 15, 2014 7:00pm

Identification: SA04c

This talk will critically review new technology diagnostic tools in transplantation to detect early graft injury and/or predict chronic injury. There will be practical approach to the use of these tools, their current usefulness, costing and limitations.
It Is Time to Change Long-term Study Designs: What Are We Evolving to and How Will These Changes Impact Our Patients, Research and Programs? iconIt Is Time to Change Long-term Study Designs: What Are We Evolving to and How Will These Changes Impact Our Patients, Research and Programs?

It Is Time to Change Long-term Study Designs: What Are We Evolving to and How Will These Changes Impact Our Patients, Research and Programs?

Feb 15, 2014 7:00pm ‐ Feb 15, 2014 7:30pm

Identification: SA04d

This talk will provide an overview from the top and focus on what we need to ensure that drugs come to transplant to be tested, where the AST should help, what is the FDA approval process for testing, how do we integrate research into clinical care, as well as patient and clinician education.